Searched for
MYLAN BIOCON STAKE
Biocon shares jump 6% as Mylan likely exits drugmaker after Rs 3,481 crore stake saleBiocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake, exiting the In...- Mylan to sell up to $363 million stake in India's Biocon, term sheet showsMylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, worth up to 34.81 billion Indian rupees ($363 million),...
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...
- CCI approves BC Asia Investments' stake acquisition in IIFL Wealth ManagementBC Asia Investments X Ltd is indirectly held by Bain Capital Investors LLC (Bain Private Equity), Bain Capital Credit Member LLC and Bain C...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon arm to buy US company Biosimilar biz for $3.34 billionBiocon Biologics (BBL) will get the global biosimilar business of Viatris in developed and emerging markets, with an estimated revenue of $...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
- Buy Biocon, target price Rs 498: Centrum BrokingBiocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 49554.00 Crore) operating in Pharmaceuticals ...
- Biocon shares gain 1% in early sessionShares of Biocon Ltd. traded 1.01 per cent up in trade at 11:03AM on Wednesday .
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Temasek, TrueNorth-CPPIB seek to invest in Biocon BiologicsEye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.
- Top stocks in focus on 10 October 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
- Biocon surges on USFDA's cancer drug approvalFor the quarter ended March 31, 2017, Biocon reported total revenue at Rs 632.10 crore and net profit stood at 203.80 crore.
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
- Biocon sets Syngene IPO price band at Rs 240-250Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...
- Syngene IPO money to fund Biocon research: ShawShaw said that Biocon has the largest biosimilar pipeline globally in phase three clinical trials and the IPO will help fund those costs.
- Mylan may buy contraceptive co Famy Care for Rs 3,000 croreMylan is said to have pipped private equity bids from Bain Capital and Advent to move closer to a deal. Hong Kong-based AIF Capital holds 1...
- Biocon's Q3 net profit dips by 15.78% to Rs 84.85 croreThe Bangalore-based firm gave up 70% of its stake in Axicorp last April for a consideration of 40 million euros to the original promoters.
- M&As help small pharma cos make it bigConcord Biotech, a small Ahmedabad-based biotechnology firm, on Tuesday shipped its first consignment to its new $1.2bn US-based parent, My...
Load More
